These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 25420053)

  • 1. Pathophysiologic and treatment strategies for cardiovascular disease in end-stage renal disease and kidney transplantations.
    Ghanta M; Kozicky M; Jim B
    Cardiol Rev; 2015; 23(3):109-18. PubMed ID: 25420053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [REIN Report 2011--summary].
    Couchoud C; Lassalle M; Jacquelinet C
    Nephrol Ther; 2013 Sep; 9 Suppl 1():S3-6. PubMed ID: 24119584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular risk assessment before and after kidney transplantation.
    Glicklich D; Vohra P
    Cardiol Rev; 2014; 22(4):153-62. PubMed ID: 24896248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular morbidity and mortality after kidney transplantation.
    Stoumpos S; Jardine AG; Mark PB
    Transpl Int; 2015 Jan; 28(1):10-21. PubMed ID: 25081992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Recent advances in the prevention of cardiovascular morbidity and mortality in end-stage renal disease: role of anemia, hyperparathyroidism and calcifications].
    Del Vecchio L; Pozzoni P; Limardo M; Caruso S; Fortunato M; Pontoriero G; Locatelli F
    G Ital Nefrol; 2007; 24 Suppl 38():25-32. PubMed ID: 17922444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategies for improving long-term survival in patients with ESRD.
    Nolan CR
    J Am Soc Nephrol; 2005 Nov; 16 Suppl 2():S120-7. PubMed ID: 16251247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cardiovascular disease after renal transplantation].
    Montanaro D; Gropuzzo M; Tulissi P; Boscutti G; Risaliti A; Baccarani U; Adani GL; Sainz M; Bresadola F; Mioni G
    G Ital Nefrol; 2004; 21 Suppl 26():S53-66. PubMed ID: 15732047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular calcification in nondialyzed patients with chronic kidney disease.
    Qunibi WY
    Semin Dial; 2007; 20(2):134-8. PubMed ID: 17374087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonalcoholic fatty liver disease (NAFLD)--is it a new marker of hyporesponsiveness to recombinant human erythropoietin in patients that are on chronic hemodialysis?
    Orlic L; Mikolasevic I; Lukenda V; Racki S; Stimac D; Milic S
    Med Hypotheses; 2014 Dec; 83(6):798-801. PubMed ID: 25456789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The candidate for renal transplantation work up: medical, urological and oncological evaluation.
    Cabello Benavente R; Quicios Dorado C; López Martin L; Simón Rodríguez C; Charry Gónima P; González Enguita C
    Arch Esp Urol; 2011 Jun; 64(5):441-60. PubMed ID: 21705817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular disease in end stage renal disease.
    Sharma R; Pellerin D; Brecker SJ
    Minerva Urol Nefrol; 2006 Jun; 58(2):117-31. PubMed ID: 16767066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Duration of end-stage renal disease and kidney transplant outcome.
    Goldfarb-Rumyantzev A; Hurdle JF; Scandling J; Wang Z; Baird B; Barenbaum L; Cheung AK
    Nephrol Dial Transplant; 2005 Jan; 20(1):167-75. PubMed ID: 15546892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Magnesium in chronic kidney disease: challenges and opportunities.
    Kanbay M; Goldsmith D; Uyar ME; Turgut F; Covic A
    Blood Purif; 2010; 29(3):280-92. PubMed ID: 20090315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Why do patients with kidney diseases end up with a heart of stone? Disturbances in calcium-phosphate balance and chronic inflammation important causes].
    Martola L; Elinder CG; Stenvinkel P
    Lakartidningen; 2003 Dec; 100(50):4180-3. PubMed ID: 14717005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The cardiovascular risk after renal transplantation (1): Hypertension and left ventricular hypertrophy].
    Covic A; Gusbeth-Tatomir P; Covic M
    Rev Med Chir Soc Med Nat Iasi; 2001; 105(4):651-6. PubMed ID: 12092214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Metabolic disorders in renal transplant recipients].
    Mikolasević I; Jelić I; Sladoje-Martinović B; Orlić L; Zivcić-Cosić S; Vuksanović-Mikulicić S; Mijić M; Racki S
    Acta Med Croatica; 2012 Jul; 66(3):235-41. PubMed ID: 23441539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Traditional and non-traditional risk factors as contributors to atherosclerotic cardiovascular disease in end-stage renal disease.
    Yao Q; Pecoits-Filho R; Lindholm B; Stenvinkel P
    Scand J Urol Nephrol; 2004; 38(5):405-16. PubMed ID: 15764253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Obesity, metabolic syndrome and diabetes mellitus after renal transplantation: prevention and treatment.
    Wissing KM; Pipeleers L
    Transplant Rev (Orlando); 2014 Apr; 28(2):37-46. PubMed ID: 24507957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C virus infection in end-stage renal disease and kidney transplantation.
    Burra P; Rodríguez-Castro KI; Marchini F; Bonfante L; Furian L; Ferrarese A; Zanetto A; Germani G; Russo FP; Senzolo M
    Transpl Int; 2014 Sep; 27(9):877-91. PubMed ID: 24853721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.